Almi Invest and trade union Unionen have both returned with funding for Beactica, a drug discovery company based on Uppsala University research.

A month after Sutro closed an $85.4m series E round, the cancer drug developer, based on research at Stanford, has filed for a $75m initial public offering.

A month after Sutro closed an $85.4m series E round backed by Merck & Co, Celgene, Amgen and Eli Lilly, the cancer drug developer has filed for a $75m initial public offering.

Epigenomics services provider Epinomics, co-founded by Stanford University faculty and alumni, has been bought by 10x Genomics in a transaction which enables StartX to exit.

Vertex Pharmaceuticals has led a series B round for Genomics, a spinout from University of Oxford that also attracted Oxford Sciences Innovation and IP Group.

Vertex Pharmaceuticals has led a series B round for Genomics, a spinout from University of Oxford that also attracted Oxford Sciences Innovation and IP Group.

Qiming Capital and Hillhouse Capital have co-led a series C round for Eli Lilly-backed Jacobio Pharmaceuticals, which has now launched a corporate venturing arm.

Baxter Ventures has participated in a series D round for Outset Medical, a spinout of Oregon State University.

Aptus-backed Alzheon hopes to raise $40.3m in proceeds, less than half as much as it had targeted earlier this year before withdrawing plans in May.